New Formulations of Stimulants for Attention-Deficit Hyperactivity DisorderTherapeutic Potential
作者:
Daniel F Connor,
Ronald J Steingard,
期刊:
CNS Drugs
(ADIS Available online 2004)
卷期:
Volume 18,
issue 14
页码: 1011-1030
ISSN:1172-7047
年代: 2004
出版商: ADIS
关键词: Central stimulants, therapeutic use;Methylphenidate, therapeutic use;Dexmethylphenidate, therapeutic use;Dexamfetamine, therapeutic use;Pemoline, therapeutic use;Adderall, therapeutic use;SLI 381, therapeutic use;Attention deficit hyperactivity disorder,
数据来源: ADIS
摘要:
New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one immediate release and four longer-acting preparations) that have recently become available for the treatment of ADHD.While the therapeutic potential of immediate-release enantiomers of methylphenidate has not yet been clinically realised, new long-acting formulations of stimulants have changed the standard of care for children, adolescents and adults with ADHD. The longer duration of action of these once-daily compounds, and the consequent expansion of the duration of daily ADHD coverage afforded by them, has introduced the realistic possibility of reducing the overall daily burden of ADHD on affected individuals. Although more expensive, these new stimulant formulations are easier for patients to use than older stimulants, more resistant to abuse and misuse, and allow for increased privacy of ADHD treatment at school or work.
点击下载:
PDF
(318KB)
返 回